|
1
|
Siegel R, DeSantis C, Virgo K, Stein K,
Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chemotherapy in non-small cell lung
cancer, . A meta-analysis using updated data on individual patients
from 52 randomised clinical trials. Non-small Cell Lung Cancer
Collaborative Group. BMJ. 311:899–909. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Azzoli CG, Temin S and Giaccone G: 2011
Focused Update of 2009 American Society of Clinical Oncology
Clinical Practice Guideline Update on Chemotherapy for Stage IV
Non-Small-Cell. Lung Cancer. J Oncol Pract. 8:63–66. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Quoix E, Zalcman G, Oster JP, Westeel V,
Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L,
et al: Carboplatin and weekly paclitaxel doublet chemotherapy
compared with monotherapy in elderly patients with advanced
non-small-cell lung cancer: IFCT-0501 randomized, phase 3 trial.
Lancet. 378:1079–1088. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Abe T, Takeda K, Ohe Y, Kudoh S, Ichinose
Y, Okamoto H, Yamamoto N, Yoshioka H, Minato K, Sawa T, et al:
Randomized phase III trial comparing weekly docetaxel plus
cisplatin versus docetaxel monotherapy every 3 weeks in elderly
patients with advanced non-small-cell lung cancer: The intergroup
trial JCOG0803/WJOG4307L. J Clin Oncol. 33:575–581. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shirasaka T, Shimamato Y, Ohshimo H,
Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a
novel form of an oral 5-fluorouracil derivative (S-1) directed to
the potentiation of the tumor selective cytotoxicity of
5-fluorouracil by two biochemical modulators. Anticancer Drugs.
7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kubota K, Sakai H, Yamamoto N, Kunitoh H,
Nakagawa K, Takeda K, Ichinose Y, Saijo N, Ariyoshi Y and Fukuoka
M: A multi-institution phase I/II trial of triweeky regimen with
S-1 plus cisplatin in patients with advanced non-small cell lung
cancer. J Thorac Oncol. 5:702–706. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ichinose Y, Yoshimori K, Sakai H, Nakai Y,
Sugiura T, Kawahara M and Niitani H: S-1 plus cisplatin combination
chemotherapy in patients with advanced non-small cell lung cancer:
A multi-institutional phase II trial. Clin Cancer Res.
10:7860–7864. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kawahara M, Furuse K, Segawa Y, Yoshimori
K, Matsui K, Kudoh S, Hasegawa K and Niitani H; S-1 Cooperative
Study Group (Lung Cancer Working Group), : Phase II study of S-1, a
novel oral fluorouracil, in advanced non-small-cell lung cancer. Br
J Cancer. 85:939–943. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Furuse K, Kawahara M, Hasegawa K, Kudoh S,
Takada M, Sugiura T, Ichinose Y, Fukuoka M, Ohashi Y and Niitani H;
S-1 Cooperative Study Group (Lung Cancer Working Group), : Early
phase II study of S-1, a new oral fluoropyrimidine, for advanced
non-small-cell lung cancer. Int J Clin Oncol. 6:236–241. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Okamoto I, Yoshioka H, Morita S, Ando M,
Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, et al:
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel
plus carboplatin in chemotherapy-naïve patients with advanced
non-small-cell lung cancer: Results of a west Japan oncology group
study. J Clin Oncol. 28:5240–5246. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kubota K, Sakai H, Katakami N, Nishio M,
Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, Kobayashi K,
et al: A randomized phase III trial of oral S-1 plus cisplatin
versus docetaxel plus cisplatin in Japanese patients with advanced
non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol.
26:1401–1408. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo Zw and Gallo JM: Selective Protection
of 2′,2′-Difluorodeoxycytidine (Gemcitabine). J Org Chem.
64:8319–8322. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ichinose Y, Seto T, Semba H, Itoh K, Inoue
Y, Tanaka F, Araki J, Tamanoi M, Yamamoto H and Iwamoto N: UFT plus
gemcitabine combination chemotherapy in patients with advanced
non-small-cell lung cancer: A multi-institutional phase II trial.
Br J Cancer. 93:770–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakamura K, Yamaguchi T, Ishihara T, Sudo
K, Kato H and Saisho H: Phase II trial of oral S-1 combined with
gemcitabine in metastatic pancreatic cancer. Br J Cancer.
94:1575–1579. 2006.PubMed/NCBI
|
|
16
|
Kaira K, Sunaga N, Yanagitani N, Aoki H,
Kawata T, Utsugi M, Shimizu Y, Shimizu K, Hisada T, Ishizuka T and
Mori M: Phase I trial of oral S-1 plus gemcitabine in elderly
patients with non-small cell lung cancer. Anticancer Drugs.
19:289–294. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seto T, Yamanaka T, Wasada I, Seki N,
Okamoto H, Ogura T, Shibuya M, Takiguchi Y, Shinkai T, Masuda N, et
al: Phase I/II trial of gemcitabine plus oral TS-1 in elderly
patients with advanced non-small cell lung cancer: Thoracic
oncology research group study 0502. Lung Cancer. 69:213–217. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Satouchi M, Kotani Y, Katakami N, Shimada
T, Urata Y, Yoshimura S, Funada Y, Hata A, Ando M and Negoro S:
Randomized phase II study of two different schedules of gemcitabine
and oral S-1 in chemo-naïve patients with advanced non-small cell
lung cancer. J Thorac Oncol. 5:696–701. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takiguchi Y, Seto T, Ichinose Y, Nogami N,
Shinkai T, Okamoto H, Minato K, Seki N, Eguchi K, Kishi K, et al:
Long-term administration of second-line chemotherapy with S-1 and
gemcitabine for platinum-resistant non-small cell lung cancer. A
phase II study. J Thorac Oncol. 6:156–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. J Natl Cancer
Inst. 92:205–216. 2000. View Article : Google Scholar
|
|
21
|
Trotti A, Colevas AD, Setser A, Rusch V,
Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and
Rubin P: CTCAE v3.0: Development of a comprehensive grading system
for the adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kudoh S, Takeda K, Nakagawa K, Takada M,
Katakami N, Matsui K, Shinkai T, Sawa T, Goto I, Semba H, et al:
Phase III study of docetaxel compared with vinorelbine in elderly
patients with advanced non-small-cell lung cancer: Results of the
West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin
Oncol. 24:3657–3663. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gajra A and Jatoi A: Non-small-cell lung
cancer in elderly patients: A discussion of treatment options. J
Clin Oncol. 32:2562–2569. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maione P, Perrone F, Gallo C, Manzione L,
Piantedosi F, Barbera S, Cigolari S, Rosetti F, Piazza E, Robbiati
SF, et al: Pretreatment quality of life and functional status
assessment significantly predict survival of elderly patients with
advanced non-small-cell lung cancer receiving chemotherapy: A
prognostic analysis of the multicenter Italian lung cancer in the
elderly study. J Clin Oncol. 23:6865–6872. 2005. View Article : Google Scholar : PubMed/NCBI
|
